Movember, Beyond the Moustache

Movember’s priorities include mental health and suicide prevention, prostate cancer, and testicular cancer. No-Shave November is a separate cancer-awareness and fundraising campaign. The two use facial hair to start conversations, but they are not interchangeable names and do not create a universal medical checklist.

A moustache can make a stranger ask a question. The real public-health opportunity comes after the answer. Does the conversation help someone understand a symptom, prepare for a screening decision, or ask for support? Or does it end with a photograph and the familiar instruction to be strong?

Movember's priorities include mental health and suicide prevention, prostate cancer, and testicular cancer. No-Shave November is a separate cancer-awareness and fundraising campaign. The two use facial hair to start conversations, but they are not interchangeable

names and do not create a universal medical checklist.[1][2]

This feature takes the three Movember priorities in turn: what national resources say, what peer-reviewed research has and has not shown, and what has to happen after. someone decides to act. It is not an evaluation of any clinic, health system or program.

An appointment is not a test of character Encouraging men to seek care can be useful. Assuming that reluctance explains every delay is not. An appointment also requires information: which service is needed, whether it is covered, how to schedule, and what happens afterward.

MB's opening question is therefore larger than "Why don't men go?" It is "What makes the next step possible?" That question leaves room for individual decisions and institutional responsibility without deciding the answer in advance.

For The Back Office of Care, the question has four parts. Who orders the test or the referral? Who schedules it, and what happens if the first date is weeks away? Who

explains what it will cost before the person arrives? Who communicates the result, and in what words? When the owner is unclear, the task can sit undone while everyone assumes someone else has it.

A long wait with no check-in can look like a decision to skip it.

where a process can quietly stall.

Prostate screening begins with an informed discussion. The prostate-specific antigen, or PSA, blood test can help assess prostate-cancer risk, but an elevated result is not a diagnosis. Noncancerous enlargement or inflammation can also affect PSA. Additional assessment may be appropriate. Screening can also lead to false alarms, biopsies, and detection of cancers that might never have caused harm.

The American Cancer Society recommends a discussion of potential benefits, risks, and uncertainties before testing. Its guidance starts that discussion at age 50 for average-risk men expected to live at least ten more years; age 45 for higher-risk men, including Black men and those with a father or brother diagnosed before 65; and age 40 for men with more than one first-degree relative diagnosed at an early age. These are ACS recommendations, not a schedule universally shared by every medical organization. Knowing the recommendation should help someone prepare, not create a rule to ignore symptoms until a birthday. Screening concerns people without symptoms. A new urinary or other concerning change warrants a separate clinical discussion and may have other explanations.

What the largest trial of a single PSA invitation found One long-term trial is CAP, the Cluster Randomized Trial of PSA Testing for Prostate Cancer. Researchers identified men aged 50 to 69 at 573 primary care practices in England and Wales. Practices were randomized. Men at the intervention practices received one invitation for a PSA test, with further diagnostic tests if the PSA level was 3.0 ng/mL or higher. Men at the control practices received standard practice, which meant no invitation.

Of 415,357 eligible men, 98% were included in the analysis at a median follow-up of 15 years. Prostate cancer was diagnosed in 7.08% of the intervention group and 6.94% of the control group. Prostate cancer deaths were 0.69% in the intervention group (1,199 men) and 0.78% in the control group (1,451 men), a rate ratio of 0.92 (95% confidence interval 0.85 to 0.99). The authors describe this as a reduction in prostate cancer deaths, and they also state that the absolute reduction was small. Deaths from any cause were melaninblissmedia.com · Not a brand. A blueprint. Page 323.2% and 23.3%, a difference that did not reach statistical significance (rate ratio 0.97, 95% CI 0.94 to 1.01).

The invitation increased detection of low-grade and localized disease. It did not increase detection of intermediate-grade, high-grade, locally advanced or distally advanced tumors. The authors also report that 8 of the prostate cancer deaths in the intervention group (0.7%) and 7 in the control group (0.5%) were related to a diagnostic biopsy or to treatment.

Read as reporters, three limits matter. First, this was a single invitation, so the trial cannot tell us what repeated testing would do. Second, it was conducted in England and Wales, and the abstract does not report results by race, so it cannot tell us how the balance of benefit and harm looks for Black men in the United States. Third, a difference of nine hundredths of a percentage point in death rates is a population finding. It does not predict what happens to one man. That is why the discussion matters: two men can look at the same numbers and choose differently.

Black men, risk and the access question For Black men, a risk discussion should not reduce unequal outcomes to biology alone. Access to appropriate assessment, understandable information, treatment, and follow-up are also questions worth examining. Start with the conversation itself. Researchers reviewed charts for a random sample of 600 men aged 45 to 69 seen in an academic family medicine practice in South Carolina in 2019 and 2020.

A shared decision-making conversation about prostate cancer screening was documented for 7.3% of Black men and 5.3% of non-Black men, a difference that was not statistically significant. A screening PSA was ordered for 39.7% of Black men and 36.0% of non-Black men. Among all men, those with a documented conversation were more likely to be screened (71.8% versus 35.6%), and among Black men the figures were 85.0% versus 35.7%.

What that study cannot show: it is one practice, it reviewed documentation, not the visits themselves, and it shows an association, not a cause. A conversation may have happened and gone unrecorded, or men already inclined to be tested may have raised it.

It does show that, in this sample, a documented discussion was rare for every group, and the authors call for more shared decision-making and better documentation. A second group of studies uses the Veterans Affairs health system, described in these papers as a near-equal-access setting. In a nationwide VA cohort of 26,542 men who received definitive radiation for localized prostate cancer between 2000 and 2020 (8,716 Black and 17,826 White), the 10-year cumulative incidence of biochemical recurrence was 22.14% for Black men and 20.13% for White men, with a hazard ratio of 1.03 that was not statistically significant. After recurrence, Black race was associated with a lower risk of metastatic disease and of death from prostate cancer (subdistribution hazard ratio 0.72, 95% CI 0.63 to 0.82).[9] In a separate VA genomic study of 5,015 veterans with metastatic prostate cancer (1,784 Black), the authors report that survival was similar by race in the near-equal-access setting, while Black veterans were younger, had higher PSA levels at diagnosis, and lived in more deprived neighborhoods.

Those findings are retrospective, come from veterans who are not representative of all American men, and concern treatment and outcomes, not screening.

A third study complicates the picture in a useful way. In the NCI-Maryland prostate cancer case-control study of 976 men, the authors found no survival differences between African American and European American men with stage 1 or 2 disease. African American men with stage 3 or 4 disease had significantly higher prostate cancer-specific and all-case mortality, in VA and non-VA settings alike. Adjusting for baseline PSA, Gleason score and treatment attenuated but did not eliminate the gap, and African American men with advanced disease were more likely to receive hormone therapy alone.

The authors conclude that disparities emerge mainly at stage 3 or 4 diagnosis, which they say underlines the importance of early detection.[11] The abstract gives no numbers, and a case-control design cannot establish why treatment patterns differed.

Taken together, these studies do not give a single answer. They support a narrower point. The questions worth asking are about the system around the test: whether the conversation happens, whether it is understandable, whether the test is ordered, whether the result reaches the man, and whether treatment and follow-up are the same for everyone.

A N I L L U S T R A T I V E S C E N A R I O ( N O T A R E A L P E R S O N )

This is a composite built to show how the steps connect. It is not a person MB

interviewed, and nothing in it describes an actual clinic or health system.

Imagine a 47-year-old Black man whose father was diagnosed with prostate cancer at 62.

He saw a Movember post and decided to ask his primary care clinician about a PSA test. Under the ACS guidance described above, he falls into the group for whom the discussion starts at 45.

At the visit, the clinician explains benefits, risks and uncertainty, and he decides he would like the test. Now the Back Office of Care questions begin. Is the order placed during the visit or does he have to call? Does the front desk know whether his plan covers the test, and can someone tell him before he goes to the lab? Who calls with the result, and does the call explain that a high PSA is a reason for further assessment, not a diagnosis? If the result is high, who arranges the referral?

If any answer is "I assume the clinic will," that is where the process can fail.

Testicular changes are worth reporting A lump, swelling, heaviness, or a new change in how a testicle feels deserves medical evaluation. Not every change is cancer. A clinician may use an examination and ultrasound to investigate. NCI also makes clear that no standard routine screening test is used for testicular cancer.

Being aware of a new change is different from claiming a home examination can rule out cancer. Do not turn an awareness campaign into an instruction that everyone must perform a particular routine or a judgment that someone should have detected a disease earlier.

The goal is an appropriate response to a concern, not constant self-surveillance or panic. Why does timing get discussed at all? A single-center study from Mexico City retrospectively analyzed 223 men with confirmed testicular cancer treated between

January 2017 and January 2025. The median age was 26, 53.4% had non-seminomatous disease, and 25.6% had a diagnostic delay of more than six months. All 13 deaths occurred in men with stage IIIC disease, and 56 of the 57 men with delay progressed.

Mortality was associated with delay of more than six months (odds ratio 10.3), poor-risk disease classification, and a very high tumor-marker level. The authors note that the association between delay and mortality was largely mediated by stage at presentation.

That study cannot be applied directly to the United States. It is one tertiary referral center with a retrospective design and a small number of deaths, and the authors used penalized regression for mortality because of complete separation in the data. It also cannot tell us why the delays happened. It supports a modest statement: in this cohort, long delays travelled with advanced stage, and the authors describe testicular cancer as highly curable. A new change should be evaluated promptly. That is not a reason to blame a man who waited, because the study did not measure the reasons. Give mental-health conversations room for an honest answer

"How are you?" is an opening only if there is space for something other than "fine." A more specific invitation can help: "You have seemed overwhelmed. Would it help if I listened, helped find support, or stayed while you made a call? "That is suggested conversation language, not a diagnostic tool. Do not promise secrecy if someone describes immediate danger. In the United States, call or text 988 for support with emotional distress or a suicidal crisis. People can also contact the service about someone else. For an immediate life-threatening emergency, call 911. Support should not be offered only when someone can explain themselves calmly or make their distress convenient for other people. It should also avoid demanding a public disclosure as evidence that a man is taking health seriously.

What does research say about programs built for men? A 2026 systematic review searched six databases through December 2025 and included 17 articles evaluating 14 suicide prevention interventions in male-only samples. The authors state that men have two to four times the suicide mortality of women and are less likely to seek help, with disparities linked to restrictive masculine norms and stigma. Only one included study assessed suicide deaths, and none occurred. Among randomized trials, there were no significant effects on suicide attempts, suicidal ideation or depression. Evidence on help-seeking behaviors and intentions was mixed, and help-seeking attitudes did not improve.

Risk of bias was generally moderate to high. That finding does not say men cannot be helped or that outreach is pointless. It says the evaluated interventions have not yet shown clear effects on the outcomes measured. The review also grouped gender-tailoring strategies into seven categories, including outreach and recruitment, delivery modalities, male representation and role modeling, and communication and action orientation, and the authors call for better evaluation.

For a campaign, the honest summary is that a slogan is not an intervention, and its effect is an open question until measured. The follow-through belongs in the story After someone agrees to seek help, who identifies the right service? What happens if there is a wait? Does someone explain confidentiality and cost? Those are questions for clinicians, programs, and organizations, not assumptions that every service is failing.

Q U E S T I O N S T O A S K A N D S T E P S T O T A K E

For a PSA discussion:

What are the benefits and risks of testing for me? What happens if the result is high? What would the next step be, and who arranges it? For any test or referral: Who places the order? How will I be told the result, and by when? What will I be billed, and who can give me that estimate before I go?

For a new testicular change: Who can see me soon? Should I ask for an examination and an ultrasound? What should I do if the change grows or the appointment is far away? For a friend who is struggling: Say what you have noticed. Offer to listen, help find support, or stay while they make a call.

For distress or a suicidal crisis: In the United States, call or text 988. You can also contact 988 about someone else. For an immediate life-threatening emergency, call 911. If you are a clinic or program: Can a patient tell, from your materials alone, who owns each step after the first visit?

W H A T T H E E V I D E N C E C A N A N D C A N N O T T E L L U S

It can tell us that PSA screening is associated with a small reduction in prostate cancer deaths in one large trial of men in England and Wales, alongside detection of low-grade disease and some deaths linked to biopsy or treatment.

It can tell us that long diagnostic delays travelled with advanced testicular cancer in one Mexican referral center, and that some outcome gaps by race look different at different stages and in different health systems.

It cannot tell us how any particular clinic, insurer or program in New York or anywhere else performs.

It cannot tell us whether the CAP results apply equally to Black men in the United States. The abstract does not report results by race.

It cannot tell us why a given man delayed seeking care, or which outreach approach works. The review of suicide-prevention programs for men found limited evidence.

MB will continue conversations about male breast cancer and male survivors of domestic violence alongside this month's work. Those are our editorial priorities, not additional official Movember categories.A campaign can begin with a visible gesture. Its value should not end there. Keep the conversation, the questions, and the expectation of a meaningful response after November is over.

General information, not individual medical advice. For emergencies, seek immediate help. The conversation continues.

Sources: (P E E R - R E V I E W E D W O R K R E T R I E V E D F R O M P U B M E D ; D O I L I N K S I N C L U D E D ) Movember. Health priorities: mental health and suicide prevention, prostate cancer, testicular cancer. Movember Foundation website. Cited in the Nov. 5 MB draft; not re-retrieved in this session. 

[2] No-Shave November. Campaign guide. No-Shave November website. Cited in the Nov. 5 MB draft; not re-retrieved in this session.

[3] National Cancer Institute. Prostate cancer pages on prostate changes, PSA testing and screening (cited in the draft as "NCI: prostate changes" and "NCI: prostate screening").

[4] American Cancer Society. Prostate cancer screening guidance (cited in the draft as "ACS:prostate screening guidance"). Not re-retrieved in this session.

[5] National Cancer Institute. Testicular cancer pages on symptoms, diagnosis and screening (cited in the draft as "NCI: testicular symptoms," "testicular diagnosis," "testicular screening"). Not re-retrieved in this session.

[6] 988 Suicide & Crisis Lifeline. Get help; support someone else. Cited in the Nov. 5 MB draft; not in this session.

[7] Martin RM, Turner EL, Young GJ, Metcalfe C, Walsh EI, Lane JA, et al. Prostate-specific antigenscreening and 15-year prostate cancer mortality: a secondary analysis of the CAP randomizedclinical trial. JAMA. 2024;331(17):1460-1470. DOI: https://doi.org/10.1001/jama.2024.4011 (PMID38581198)

[8] Shungu N, Le J, Robinson NE, Diaz V. Prostate cancer screening shared decision making and prostate-specific antigen testing in Black and non-Black men in primary care in South Carolina. South Med J. 2026;119(6):303-307. DOI: https://doi.org/10.14423/SMJ.0000000000001980 (PMID42229551)

[9] Morgan KM, Riviere P, Nelson TJ, Guram K, Deshler LN, Sabater Minarim D, et al. Androgen deprivation therapy and outcomes after radiation therapy in Black patients with prostate cancer. JAMA Netw Open. 2024;7(6):e2415911. DOI: https://doi.org/10.1001/jamanetworkopen.2024.15911 (PMID 38857047)

[10] Valle LF, Li J, Desai H, Hausler R, Haroldsen C, Chatwal M, et al. Somatic tumor next-generation sequencing in US veterans with metastatic prostate cancer. JAMA Netw Open. 2025;8(5):e259119. DOI: https://doi.org/10.1001/jamanetworkopen.2025.9119 (PMID 40354055)

[11] Minas TZ, Butler EN, Mwamburi SM, Dorsey TH, Bedi D, Dean-Colomb W, et al. Stage-specific racial disparities in prostate cancer survival outcomes. Prostate. 2026. DOI: https://doi.org/10.1002/pros.70265 (PMID 42837052)

[12] Cantellano-Orozco M, Anceno A, Silva-Mendoza CA, Garzon-Ortega VH, Hosseini H, Angulo-Sanchez JR, et al. Prognostic impact of diagnostic delay in testicular cancer: a single-center Mexican cohort study with machine learning risk prediction. Clin Genitourin Cancer. 2026. DOI: https://doi.org/10.1016/j.clgc.2026.102666 (PMID 42823227)

[13] Shi L, Sutori S, Logdberg U, Carli V, Eliasson ET. Effectiveness and gender-tailoring of suicide prevention interventions for men: a systematic review. BMC Public Health. 2026. DOI:https://doi.org/10.1186/s12889-026-28269-1 (PMID 42337495)